Holen Sie sich die Stockscreener-App
5.41
5.84%
-0.35
Schlusskurs vom Vortag:
$5.76
Offen:
$5.67
24-Stunden-Volumen:
256.05K
Relative Volume:
0.41
Marktkapitalisierung:
$176.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.25M
KGV:
-4.5616
EPS:
-1.186
Netto-Cashflow:
$-22.80M
1W Leistung:
-7.60%
1M Leistung:
-0.30%
6M Leistung:
-23.72%
1J Leistung:
+48.19%
1-Tages-Spanne:
$5.40
$5.7338
1-Wochen-Bereich:
$5.34
$5.86
52-Wochen-Spanne:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Firmenname
Sagimet Biosciences Inc
Sektor
Branche
Telefon
(650) 561-8600
Adresse
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
5.42 | 187.32M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.43 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.76 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
725.02 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.64 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.26 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-03 | Eingeleitet | Guggenheim | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2025-08-11 | Eingeleitet | Wedbush | Outperform |
| 2025-08-07 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-24 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-12-06 | Eingeleitet | Oppenheimer | Outperform |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Herabstufung | Goldman | Buy → Neutral |
| 2024-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-25 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-08 | Eingeleitet | Goldman | Buy |
| 2023-08-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-08 | Eingeleitet | Piper Sandler | Overweight |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
Sagimet Biosciences (SGMT) Projected to Post Earnings on Wednesday - MarketBeat
Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf. - MarketBeat
Bull Bear: How does Sagimet Biosciences Inc score in quality rankings2025 Macro Impact & Consistent Profit Alerts - baoquankhu1.vn
SGMT Should I Buy - Intellectia AI
SGMT: Lead FASN inhibitor advances in MASH and acne, with pivotal trials and regulatory milestones ahead - TradingView
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences - The Manila Times
Sagimet Biosciences to Participate in Upcoming Investor Conferences in March 2026 - Quiver Quantitative
Biotech Sagimet lines up three March investor conferences - Stock Titan
SGMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SGMTSagimet Biosciences Inc. Latest Stock News & Market Updates - Stock Titan
Sagimet (NASDAQ: SGMT) CMO receives 88,000-share option and 44,000 RSUs - Stock Titan
Sagimet Biosciences (SGMT) CFO awarded 88,000 options and 44,000 RSUs - Stock Titan
What is the long term forecast for Sagimet Biosciences Inc. stockChart Signals & Short-Term Swing Trade Alerts - mfd.ru
Can Sagimet Biosciences Inc. continue delivering strong returnsTrade Volume Report & Smart Money Movement Alerts - mfd.ru
Sagimet (SGMT) CEO granted 256k options and 128k RSUs in Form 4 - Stock Titan
Growth Value: Is Sagimet Biosciences Inc in a consolidation phaseJuly 2025 Retail & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Sagimet Biosciences (NASDAQ:SGMT) vs. AC Immune (NASDAQ:ACIU) Financial Survey - Defense World
Don't Ignore The Insider Selling In Sagimet Biosciences - simplywall.st
Sagimet Biosciences Showcases FASN Strategy, MASH Phase II Timeline and Acne Data at Guggenheim Conference - MarketBeat
Will Sagimet Biosciences Inc. face regulatory challengesWeekly Loss Report & Safe Entry Momentum Stock Tips - mfd.ru
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero - MSN
Top Sagimet Executives Quietly Unload Shares in Coordinated Insider Move - TipRanks
David Happel Sells 12,101 Shares of Sagimet Biosciences (NASDAQ:SGMT) Stock - MarketBeat
Is Sagimet Biosciences Inc. stock trending bullish2025 Volume Leaders & Free Safe Capital Growth Stock Tips - mfd.ru
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences - The Manila Times
Hear Sagimet Biosciences at Guggenheim and Oppenheimer investor events - Stock Titan
A Look At Sagimet Biosciences (SGMT) Valuation After Denifanstat’s Phase 3 Acne Trial Success - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: Thermo Fisher (TMO), Tenet Healthcare (THC) - The Globe and Mail
Sagimet Biosciences (NASDAQ:SGMT) Coverage Initiated by Analysts at Guggenheim - Defense World
After Clearing Up Acne, Sagimet Stock Rises - Barron's
Sagimet a new buy at Guggenheim on promise of MASH, acne asset - Seeking Alpha
Sagimet Biosciences (NASDAQ:SGMT) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
Sagimet Biosciences' (SGMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
New acne mechanism shows 1-year durability in Phase III, says Sagimet - The Pharma Letter
Sagimet Therapeutics: Strengthened FASN-Inhibition Safety Profile and Advancing Phase 2 Programs Support Buy Rating - TipRanks
Sagimet stock rises after positive Phase 3 safety data for acne drug By Investing.com - Investing.com South Africa
Sagimet stock rises after positive Phase 3 safety data for acne drug - Investing.com Australia
Sagimet Biosciences announces license partner Ascletis issues results for ASC40 - TipRanks
Sagimet Biosciences Reports Positive Phase 3 Acne Data - TipRanks
Sagimet Biosciences Inc Announces Positive Phase 3 Acne Trial Results - TradingView
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne - The Manila Times
Sagimet’s Denifanstat: China Phase III Safety Data Isn’t A Negative Signal (NASDAQ:SGMT) - Seeking Alpha
Sagimet down as Chinese partner posts late-stage trial data for acne therapy - MSN
Sagimet Biosciences (NASDAQ:SGMT) Stock Rating Upgraded by Barclays - MarketBeat
Once-a-day acne pill shows 40-week safety in 240 Chinese patients - stocktitan.net
Barclays Initiates Coverage of Sagimet Biosciences (SGMT) with Equal-Weight Recommendation - Nasdaq
Barclays Initiates Coverage on Sagimet Biosciences With Equal Weight Rating, $8 Price Target - marketscreener.com
Is Sagimet Biosciences Inc stock influenced by commodity pricesWeekly Profit Analysis & Reliable Breakout Forecasts - baoquankhu1.vn
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Sagimet Biosciences enters global license agreement with TAPI - MSN
Finanzdaten der Sagimet Biosciences Inc-Aktie (SGMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sagimet Biosciences Inc-Aktie (SGMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chauche Thierry | Chief Financial Officer |
Feb 10 '26 |
Sale |
5.36 |
1,312 |
7,033 |
15,688 |
| Martins Eduardo Bruno | Chief Medical Officer |
Feb 10 '26 |
Sale |
5.36 |
3,640 |
19,511 |
103,296 |
| Rozek Elizabeth | Chief Legal & Admin. Officer |
Feb 10 '26 |
Sale |
5.36 |
2,622 |
14,054 |
190,959 |
| Kemble George | Executive Chairman |
Nov 20 '25 |
Sale |
7.69 |
37,688 |
289,979 |
81,005 |
4.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):